ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

AFIP prognostic model: progression-free survival for gastrointestinal stromal tumors (GISTs) of the stomach, small intestine, and rectum by mitotic rate and tumor size*

AFIP prognostic model: progression-free survival for gastrointestinal stromal tumors (GISTs) of the stomach, small intestine, and rectum by mitotic rate and tumor size*
Tumor size
(cm)		 Percent of patients progression free during long-term follow-up by primary site
Gastric Jejunum/ileum Duodenum Rectum
Mitotic rate (HPF): ≤5/50
≤2 100 100 100 100
2 to 5 98.1 95.7 91.7 91.5
5 to 10 96.4 76 66* 43*
>10 88 48
Mitotic rate (HPF): >5/50
≤2 100Δ 50Δ – 46
2 to 5 84 27 50 48
5 to 10 45 15 14* 29*
>10 14 10
Based on long-term follow-up studies on 1055 gastric, 629 small intestinal, 144 duodenal, and 111 rectal cancers.
AFIP: Armed Forces Institute of Pathology; HPF: high-power fields.
* Data are combined for tumors >5 cm.
¶ Mitotic rate is counted in an area of 5 square millimeters (mm2) on the glass slide section. For older microscopes with traditional field size optics, 50 HPF is equivalent to 5 mm2. For modern microscopes with wider 40× lenses/fields, 20 HPF is equivalent to 5 mm2. If necessary, the field of view should be measured to determine the actual number of HPF required to cover a 5 mm2 area.[1]
Δ Small number of cases.
Reference:
  1. Rubin BP, Blanke CD, Demetri GD, et al. Protocol for the examination of specimens from patients with gastrointestinal stromal tumor (GIST): Based on AJCC/UICC TNM, 7th edition, College of American Pathologists (CAP), Washington 2013.
Adapted from: Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23:70.
Graphic 60930 Version 9.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟